US 12,292,450 B2
Examination method for dementia or risk thereof
Ren Kimura, Haga-gun (JP); Hisashi Tsujimura, Utsunomiya (JP); Masaru Tsuchiya, Saitama (JP); Satoko Soga, Sumida-ku (JP); Noriyasu Ota, Shimotsuke (JP); and Hunkyung Kim, Asaka (JP)
Assigned to KAO CORPORATION, Tokyo (JP)
Appl. No. 17/609,945
Filed by KAO CORPORATION, Tokyo (JP)
PCT Filed May 19, 2020, PCT No. PCT/JP2020/019780
§ 371(c)(1), (2) Date Nov. 9, 2021,
PCT Pub. No. WO2020/235559, PCT Pub. Date Nov. 26, 2020.
Claims priority of application No. 2019-094474 (JP), filed on May 20, 2019; and application No. 2020-001652 (JP), filed on Jan. 8, 2020.
Prior Publication US 2022/0206016 A1, Jun. 30, 2022
Int. Cl. G01N 33/68 (2006.01)
CPC G01N 33/6896 (2013.01) [G01N 33/6812 (2013.01); G01N 33/6848 (2013.01); G01N 2800/2814 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method for examining mild cognitive impairment or dementia, or a risk thereof, the method comprising:
measuring an amount of stereoisomers of proline in a biological sample collected from a subject; and
comparing a level of D-proline with a reference value,
wherein the level of D-proline is a chiral balance of proline of formula 1 below:
{amount of D-proline/(amount of D-proline+amount of L-proline)}×100, and
wherein when the chiral balance of proline of formula 1 is less than 0.38%, from 0.38% to 0.45%, or more than 0.45%, the subject is evaluated as likely to be a healthy individual, an individual with mild cognitive impairment, or a dementia patient, respectively.